Lifeward (NASDAQ:LFWD) Posts Quarterly Earnings Results, Misses Expectations By $0.06 EPS

Lifeward (NASDAQ:LFWD) issued its quarterly earnings data on Friday. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.06), Zacks reports. The business had revenue of $6.20 million during the quarter, compared to the consensus estimate of $6.31 million. Lifeward had a negative return on equity of 137.91% and a negative net margin of 121.80%. Lifeward updated its FY 2025 guidance to EPS.

Lifeward Stock Performance

Shares of Lifeward stock traded up $0.08 during trading hours on Friday, hitting $0.60. The company’s stock had a trading volume of 773,562 shares, compared to its average volume of 299,648. The business has a 50 day moving average price of $0.65 and a two-hundred day moving average price of $0.83. Lifeward has a 12-month low of $0.50 and a 12-month high of $4.00. The company has a market cap of $9.39 million, a PE ratio of -0.19 and a beta of 0.20.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Lifeward in a research report on Wednesday, October 8th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $9.00.

About Lifeward

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke.